Zota Health Care Q1 FY27: Davaindia drives growth, but marketing and expansion costs bite

Zota Health Care began FY27 with a sharp jump in scale. Consolidated revenue from operations for Q1 FY27 stood at INR 173.60 crore, up 67.6 percent year-on-year as stated by management on the earnings call. The quarter was driven primarily by Davaindia, the company’s private-label generic pharmacy chain, which continues to expand aggressively across states.

The headline margins at the gross level remained strong. Gross profit was INR 107.56 crore and gross margin improved to 61.96 percent. But the income statement also shows the trade-off Zota is making. Operating costs rose sharply, led by employee costs linked to store additions and a steep increase in advertising and marketing. As a result, Q1 FY27 reported EBITDA was negative at INR -9.55 crore and PAT was a loss of INR -43.94 crore.

Davaindia is now the core business

The investor presentation shows the business mix has changed decisively. In Q1 FY27, Davaindia contributed 83 percent of revenue contribution, while domestic operations were 4 percent, exports 3 percent, and Everyday Herbal 3 percent.

Davaindia’s scale is visible in both store count and operating KPIs. As of June 30, 2026, the network stood at 2,825 stores, split between 1,855 COCO stores and 970 FOFO stores. Management said the company added 264 stores during the quarter, and the call also noted closures as part of regular optimization, resulting in net additions.

The presentation also highlights operating momentum in COCO stores. Quarterly COCO GMV increased to INR 115.69 crore in Q1 FY27, and quarterly footfalls reached 44.2 lakh. Average wallet spend in COCO improved to INR 262 in Q1 FY27 from INR 235 in Q4 FY26. FOFO stores delivered quarterly GMV of INR 48.33 crore with quarterly footfalls of 15.8 lakh.

A key investor question is whether the chain can mature into a stable, profitable network. Management addressed this directly in the call, stating that stores typically mature in 12 to 18 months, reaching monthly revenue per store of roughly INR 2.2 lakh to INR 2.5 lakh. Over the next three to four years, management indicated monthly revenue can rise further, potentially reaching INR 6 lakh to INR 7 lakh per month.

Financial snapshot: growth, strong gross profit, weak EBITDA

Below is a compact view of the quarter’s consolidated financials and key comparisons disclosed in the presentation.

The quarter also illustrates how quickly operating expenses can move in a retail rollout model. Employee costs increased to INR 61.13 crore, and other expenses rose materially. Management attributed the rise in other expenses largely to advertising and marketing.

Marketing push is deliberate, but near-term profitability is pressured

Management quantified the change in marketing intensity. On the call, it stated that total advertising and marketing spend for all of FY26 was around INR 18 crore, while Q1 FY27 alone saw spend of roughly INR 15 crore to INR 17 crore. The CEO explained the rationale: selling generics at scale in India requires consumer awareness building and a shift in buying habits.

Importantly, management cautioned investors not to annualize the Q1 run-rate mechanically, because brand ambassador fees and ad production costs can be lumpy. When pressed for a budget range, it guided marketing spend for FY27 at around INR 40 crore to INR 45 crore.

This marketing spike is one of the clearest explanations for why Q1 FY27 profitability deteriorated despite higher revenue. The company also pointed to input cost inflation as a reason for some margin pressure versus the prior quarter, citing higher packaging and bottle costs.

Store maturity and operating leverage are the near-term focus

Zota’s operational narrative is now tied to store-level maturity and the pace of new openings. In the management commentary included in the presentation, the chairman said the company intends to moderate the pace of expansion during Q2 FY27 and closely observe operating trends across newly added stores. The aim is to improve store productivity and execution before the next phase of expansion.

In the Q and A, management also outlined a simple store economics framework. It described a typical store breakeven around INR 2.5 lakh of monthly revenue, given a gross margin assumption around 60 percent and operating costs around INR 1.25 lakh to INR 1.30 lakh per month, with costs rising over time due to inflation. The implication is straightforward: as the cohort of newer stores ramps from roughly INR 1.6 lakh per month towards maturity levels, operating leverage should improve.

Management also gave explicit direction on profitability trajectory. It stated that reported EBITDA, which was positive in the previous quarter but negative in Q1 FY27, is expected to return to positive from next quarter onwards. For pre Ind AS profitability and cash generation, it guided that cash breakeven could be achieved within the next two to three quarters, potentially by Q4 FY27 or Q1 FY28.

A notable accounting detail also surfaced. Management explained that depreciation and finance costs are elevated partly due to Ind AS 116 lease accounting. It quantified that depreciation was about INR 27 crore and finance costs about INR 6.35 crore for the quarter, and around INR 18.5 crore to INR 19 crore of this combined impact relates to rentals under Ind AS.

Smaller verticals: Domestic, exports, and Everyday Herbal

While Davaindia dominates, the company continues to operate domestic marketing and exports, and it has expanded into OTC and wellness through Everyday Herbal Group.

The presentation notes that Zota holds an 87.78 percent stake in the Everyday Herbal Group, positioning it as backward integration and an expansion in OTC. It states OTC products account for around 30 percent of SKUs and that FY26 OTC revenue contribution was 27 percent.

Exports remain present but smaller in the current mix. The company highlighted 30 plus export markets served and 325 product approvals out of 586 dossier applications in the presentation. In Q1 FY27, export revenue was INR 5.74 crore.

Takeaways for investors

Zota’s Q1 FY27 results show a company scaling fast in organized generic pharmacy retail, with strong gross margins and expanding store productivity indicators, but also sharp near-term pressure on profitability due to marketing intensity and expansion-linked overheads.

The next few quarters will likely be judged on three measurable signals already discussed by management: whether the newer store cohorts continue to ramp towards maturity levels, whether marketing spend normalizes after a front-loaded quarter, and whether reported EBITDA stays positive from Q2 onwards as guided. If those pieces fall into place, Zota’s model could move from a high-growth rollout story into a more predictable operating leverage phase in FY27.